A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)

A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)

Abstract Background Gefitinib (G) is a recommended molecular‐targeted agent for elderly patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC). Docetaxel (Doc) and pemetrexed (Pem) have similar efficacies, and either is often used as the sole agent during tre...

Full description

Bibliographic Details
Main Authors: Kazuhiro Asami, Masahiko Ando, Takashi Nishimura, Takashi Yokoi, Atsuhisa Tamura, Koichi Minato, Masahide Mori, Fumitaka Ogushi, Akiyoshi Yamamoto, Hiroshige Yoshioka, Masaaki Kawahara, Shinji Atagi
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Thoracic Cancer
Subjects:
chemotherapy
elderly
epidermal growth factor receptor mutation
gefitinib
non‐small cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14465

Similar Items

Similar Items